Industry giants like Takeda Pharmaceuticals, Pfizer, Novartis, and Bayer are revolutionizing treatment landscapes, paving the way for enhanced patien ...

Chicago Partners Investment Group LLC purchased a new position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) in the ...

NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a generative AI software leader in clinical trial analytics, is pleased to highlight recent corporate ...

Incyte Corporation INCY is scheduled to report fourth-quarter and full-year 2024 results on Feb. 10, before the opening bell.

Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Fractyl Health, Inc. (GUTS – Research Report) yesterday and set a ...

I worked closely with NCI’s Investigational Drug Branch (IDB) from 1990-2016, including as a principal investigator of one of ...

In the last week, the United States market has stayed flat, though it is up 23% over the past year, with earnings anticipated to grow by 15% annually over the next few years. In this context of robust ...

In a report released today, Jason Gerberry from Bank of America Securities reiterated a Hold rating on Amphastar Pharmaceuticals (AMPH – ...

Exelixis (NASDAQ:EXEL – Get Free Report) had its price target raised by research analysts at UBS Group from $30.00 to $34.00 ...

Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company with a market capitalization of $9.4 billion focused on developing and commercializing novel therapies for cancer treatment, stands at a ...